Pomerantz Law Firm Files Class Action Suit Against Tenax Therapeutics, Inc.

Pomerantz Law Firm Files Class Action Against Tenax Therapeutics

On November 12, 2026, Pomerantz LLP, a reputable law firm known for its expertise in corporate litigation, announced the initiation of a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) and several of its key executives. This legal action was filed in the United States District Court for the Middle District of North Carolina, documented as case number 26-cv-01624. The lawsuit aims to represent all persons and entities that purchased or acquired Tenax securities between November 13, 2023, and August 7, 2026, also referred to as the 'Class Period.' The action seeks to recover damages attributed to alleged violations of federal securities laws by the defendants.

Background on Tenax Therapeutics

Tenax Therapeutics is a developmental-stage pharmaceutical company that focuses on innovative cardiopulmonary therapies. Among its pipeline of products, the company’s lead candidate is levosimendan, which is being evaluated as a potential treatment for pulmonary hypertension in patients with heart failure and preserved ejection fraction (PH-HRpEF). Prior to the Class Period, Tenax conducted the Phase 2 HELP study of levosimendan, reporting promising results that indicated a significant improvement in patients’ ability to walk six minutes, a key metric for assessing heart and lung function.

Allegations Against Tenax and Defendants

The complaint filed by Pomerantz alleges that Tenax’s executives made materially false and misleading statements regarding the firm’s business operations and financial prospects related to the drug TNX-103. Specifically, the lawsuit claims that the defendants overstated the efficacy of TNX-103, leading investors to believe it was more effective than it truly was. As such, the overall clinical and commercial prospects for this drug were also misrepresented, resulting in misleading public statements that misled shareholders throughout the Class Period.

Emerging Truth and Market Reaction

The truth about TNX-103's prospects began to surface on August 10, 2026, when Tenax released the disappointing topline results from its Phase 3 LEVEL clinical trial. According to this announcement, TNX-103 failed to achieve its primary endpoint as it did not demonstrate a significant improvement in the six-minute walk distance when compared to a placebo. Furthermore, the press release disclosed that the drug did not meet secondary endpoints, which only reinforced concerns among investors. In the wake of this news, Tenax’s stock price plummeted by approximately 89.77%, losing roughly $12.06 per share, closing at around $1.38.

Investor Guidance and Next Steps

Investors who acquired Tenax securities during the Class Period are encouraged to consider their options as the deadline to become a lead plaintiff is set for December 28, 2026. A copy of the formal complaint can be accessed via Pomerantz’s website. Interested parties can also reach out to Danielle Peyton for further discussions regarding the lawsuit.

Pomerantz LLP: A Legacy of Advocacy

Pomerantz LLP has established a strong foothold in the field of corporate and securities class action litigation, spearheaded by its founder, Abraham L. Pomerantz, a significant figure in the class action realm. Over its 85+ year history, Pomerantz has championed the rights of investors and secured substantial financial recoveries for victims of securities fraud and corporate misconduct. Current clients can take solace in the firm's extensive experience and commitment to protecting shareholder interests.

For more information about this class action lawsuit or Pomerantz LLP, please visit their official website or contact their offices directly. Interested investors are highly encouraged to act swiftly to protect their rights as stakeholders in Tenax Therapeutics.